Cancer Immunology Reserch

Cancer Immunol Res. 2024 Oct 21. doi: 10.1158/2326-6066.CIR-24-0051. Online ahead of print. ABSTRACT B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy has been approved for the treatment of relapsed and refractory multiple myeloma (RRMM); however, whether patients have long-term response has yet to be established. We investigated the feasibility of CBG-002, an … Read more

Cancer Immunol Res. 2024 Oct 15. doi: 10.1158/2326-6066.CIR-24-0138. Online ahead of print. ABSTRACT The T cell antigen coupler (TAC) is a chimeric receptor that facilitates tumor antigen-specific activation of T cells by co-opting the endogenous T cell receptor complex in the absence of tonic signaling. Previous data demonstrates that TAC affords T cells with the … Read more

Cancer Immunol Res. 2024 Oct 15. doi: 10.1158/2326-6066.CIR-24-0416. Online ahead of print. ABSTRACT Resistance to immune checkpoint inhibitors (ICIs) is common, even in tumors with T cell infiltration. We thus investigated consequences of ICI-induced T cell infiltration in the microenvironment of resistant tumors. T cells and neutrophil numbers increased in ICI-resistant tumors following treatment, in … Read more

Cancer Immunol Res. 2024 Oct 10. doi: 10.1158/2326-6066.CIR-23-1092. Online ahead of print. ABSTRACT The survival rate of glioma patients has not significantly increased in recent years despite aggressive treatment and advances in immunotherapy. The limited response to treatments is partially attributed to the immunosuppressive tumor microenvironment, where regulatory T cells (Tregs) play a pivotal role … Read more

Cancer Immunol Res. 2024 Oct 8. doi: 10.1158/2326-6066.CIR-23-0639. Online ahead of print. ABSTRACT Neoantigen-targeted therapy holds an array of benefits for cancer immunotherapy, but the identification of peptide targets with tumor rejection capacity remains a limitation. To better define the criteria dictating tumor rejection potential, we examined the capacity of high-magnitude T cell responses induced … Read more

Cancer Immunol Res. 2024 Oct 4. doi: 10.1158/2326-6066.CIR-24-0089. Online ahead of print. ABSTRACT The histone methyltransferase enhancer of zeste homolog 2 (EZH2) plays important roles in T-cell differentiation, proliferation and function. Previous studies have demonstrated that genetic deletion of EZH2 in CD8+ or total T cells impairs their antiviral and antitumor activity, cytokine production and … Read more

Cancer Immunol Res. 2024 Oct 1;12(10):1309. doi: 10.1158/2326-6066.CIR-12-10-WWR. NO ABSTRACT PMID:39350684 | DOI:10.1158/2326-6066.CIR-12-10-WWR

Cancer Immunol Res. 2024 Sep 30. doi: 10.1158/2326-6066.CIR-23-1027. Online ahead of print. ABSTRACT Ovarian cancers and microsatellite stable (MSS) colorectal cancers (CRC) are insensitive to anti-PD1 immunotherapy, and new immunotherapeutic approaches are needed. Preclinical data suggests a relationship between immunotherapy resistance and elevated angiopoietin 2 levels. We performed a phase 1 dose-escalation study of pembrolizumab … Read more

Cancer Immunol Res. 2024 Sep 16. doi: 10.1158/2326-6066.CIR-24-0037. Online ahead of print. ABSTRACT T cells expressing PD-1 in the peripheral blood (PB) of patients with tumors possess therapeutic potential; however, the immunosuppressive, PD1-triggered signaling pathway and limited proliferative capacity of PD-1+ T cells present challenges to their therapeutic application. Here, we observed no discernible distinction … Read more

Cancer Immunol Res. 2024 Sep 13:OF1-OF9. doi: 10.1158/2326-6066.CIR-23-0642. Online ahead of print. ABSTRACT Neutrophils are the primary myeloid cells that are recruited to inflamed tissues, and they are key players during colitis, being also present within the tumor microenvironment during the initiation and growth of colon cancer. Neutrophils fundamentally serve to protect the host against … Read more